Improving Lives: Breakthroughs & Collaborations - Research Report on Pfizer, Merck, Bristol-Myers Squibb, J&J and Lilly

NEW YORK, March 18, 2013 /PRNewswire/ --

Today, Wall Street Source announced new research reports highlighting Pfizer Inc. (NYSE: PFE), Merck & Co., Inc. (NYSE: MRK), Bristol Myers Squibb Co. (NYSE: BMY), Johnson & Johnson (NYSE: JNJ) and Eli Lilly & Co. (NYSE: LLY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Pfizer Inc. Research Report

New trial results show promising results for Inspara (eplerenone) in patients with acute STEMI without heart failure. In randomized, double-blind REMINDER trial involving 1, 012 patients with acute ST-segment elevation myocardial infarction (STEMI) without a history of HF or EF, eplerenone improved the outcome of the patients within first 24 hours of symptoms. Adding eplerenone to standard therapy as early as within the first 24hours of symptoms reduced heart failure-related morbidity. The REMINDER trial demonstrated a statistically significant 42.9% relative risk reduction in the primary endpoint with p < 0.0001 (95% confidence interval [CI] 0.439, 0.742) in patients with acute STEMI when eplerenone was initiated within the first 24 hours of onset of symptoms. Overall, the adverse events reported in the REMINDER trial were consistent with those already known for eplerenone, primarily hyperkalemia. This should bring good news to patients who want treatment with higher efficacy but with lower risks. The Full Research Report on Pfizer Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WallStSource.com/r/full_research_report/db02_PFE]

--

Merck & Co., Inc. Research Report

A collaboration between Merck and Luminex Corporation is leading to development of a companion diagnostic device that will be evaluated to help support patient selection for the clinical development of MK-8931, Merck's lead investigational medicine for Alzheimer's disease. MK-8931 is a novel oral beta amyloid precursor protein site cleaving enzyme (BACE) inhibitor. "Evaluation of biomarkers that may provide an indicator of disease onset and enable earlier diagnosis is an important goal toward facilitating early intervention and potentially improving the treatment of Alzheimer's disease," said Darryle D. Schoepp, Ph.D., senior vice president, head of Neuroscience and Ophthalmology at Merck Research Laboratories. "We look forward to working with Luminex to advance our ongoing clinical development program for MK-8931." Luminex, on the other hand, will be responsible for development, regulatory submission and commercialization of the candidate companion diagnostic device. The Full Research Report on Merck & Co., Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WallStSource.com/r/full_research_report/400f_MRK]

--

Bristol Myers Squibb Co. Research Report

Grants totaling $175,000 was awarded to both the American Cancer Society Eastern Division and Princeton HealthCare System (PHCS) to support comprehensive navigation services for patients with cancer both independently and as part of a collaborative effort among several hospitals in central New Jersey. Navigation is now viewed as an integral part of cancer services, with several studies linking patient navigation to improved patient outcome and survival rates. Navigators help coordinate patients' care and guide them to resources that can provide psychosocial support and address financial concerns, language or cultural issues and day-to-day needs such as transportation. "Bringing together organizations with common goals, similar programs and potentially complimentary services can lead to efficiencies in immediately tangible ways," says Murdo Gordon, SVP-Oncology, U.S. Pharmaceuticals, Bristol-Myers Squibb. "With the coming changes of the Affordable Care Act, the financial impact on organizations and individuals will likely be profound, and the entire cancer community will need to work together to address these concerns. Collaborative approaches, such as those being taken by UMCPP and the American Cancer Society, which bring together meaningful services from various providers to support a given community, is a refreshing solution." The Full Research Report on Bristol-Myers Squibb Co. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WallStSource.com/r/full_research_report/88a2_BMY]

--

Johnson & Johnson Research Report

Johnson & Johnson is proud to announce the opening of the Johnson & Johnson Innovative Center in London, one of the regional hubs being established this year in the world's leading innovation hotspots. The London innovation center aims to accelerate the best early stage science in the world and advance the development of new healthcare solutions "Britain has a worldwide reputation for excellence in innovation - the investment by Johnson & Johnson here demonstrates this and I am delighted to welcome this new center to the UK," says UK Secretary of State for Health Jeremy Hunt, who will be speaking at the Innovation Expo 2013. Johnson & Johnson Chief Scientific Officer and Worldwide Chairman, Pharmaceuticals, Paul Stoffels, MD, says, "The London Innovation Centre is part of Johnson & Johnson's broader innovation strategy to advance human health through collaboration with the world's leading scientists and entrepreneurs.  We are looking forward to collaborating within the UK, home to one of the world's thriving life sciences ecosystems."  Similar facilities are also being planned in Boston, San Francisco and, later this year, Shanghai. Each city was selected for its robust life sciences community. The Full Research Report on  Johnson & Johnson - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WallStSource.com/r/full_research_report/0ba3_JNJ]

--

Eli Lilly & Co. Research Report

Eli Lilly & Co., along with Kowa Pharmaceuticals America, Inc. is pleased to announce the results of a study evaluating the efficacy of LIVALO (pitavastatin) 4mg compared with pravastatin 40mg in reducing low-density lipoprotein cholesterol (LDL-C) in HIV-infected adults with high cholesterol or dyslipidemia. The study was designed as a superiority trial for the primary endpoint, percent reduction in LDL-C, and evaluated HIV-infected adults with dyslipidemia; with and without viral Hepatitis B or C. Dyslipidemia is common in people with HIV infection and HIV-infected adults are at a greater risk for cardiovascular disease due to many factor, including lipid abnormalities. Results showed that, after 12 weeks of therapy, pitavastatin had a significantly greater decrease in LDL-C compared with pravastatin (pitavastatin -49.4 mg/dL and pravastatin -33.6 mg/dL, 31% vs 21% reduction in LDL-C, respectively, p < 0.001). As pleased they are with the results, both companies look forward to further analysis of the data. The Full Research Report on Eli Lilly & Co. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WallStSource.com/r/full_research_report/937b_LLY]

--

Consider Wall Street Source

Tired of hearing about the latest, greatest trade opportunity... only to realize that the ship has long sailed? You need a strong, informative community in your arsenal. Join the group that has been consistently identifying momentous situations as they develop - long before they become the next top news on major financial networks.

Contact: Joe Thomas
Email: [email protected]
Main: +1-310-496-8071 (North America)

SOURCE Wall Street Source